These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36977745)

  • 1. Lonafarnib and everolimus reduce pathology in iPSC-derived tissue engineered blood vessel model of Hutchinson-Gilford Progeria Syndrome.
    Abutaleb NO; Atchison L; Choi L; Bedapudi A; Shores K; Gete Y; Cao K; Truskey GA
    Sci Rep; 2023 Mar; 13(1):5032. PubMed ID: 36977745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Tissue Engineered Blood Vessel Model of Hutchinson-Gilford Progeria Syndrome Using Human iPSC-derived Smooth Muscle Cells.
    Atchison L; Zhang H; Cao K; Truskey GA
    Sci Rep; 2017 Aug; 7(1):8168. PubMed ID: 28811655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. iPSC-Derived Endothelial Cells Affect Vascular Function in a Tissue-Engineered Blood Vessel Model of Hutchinson-Gilford Progeria Syndrome.
    Atchison L; Abutaleb NO; Snyder-Mounts E; Gete Y; Ladha A; Ribar T; Cao K; Truskey GA
    Stem Cell Reports; 2020 Feb; 14(2):325-337. PubMed ID: 32032552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysfunction of iPSC-derived endothelial cells in human Hutchinson-Gilford progeria syndrome.
    Matrone G; Thandavarayan RA; Walther BK; Meng S; Mojiri A; Cooke JP
    Cell Cycle; 2019 Oct; 18(19):2495-2508. PubMed ID: 31411525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of angiogenic incompetence in Hutchinson-Gilford progeria via downregulation of endothelial NOS.
    Gete YG; Koblan LW; Mao X; Trappio M; Mahadik B; Fisher JP; Liu DR; Cao K
    Aging Cell; 2021 Jul; 20(7):e13388. PubMed ID: 34086398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and Cellular Mechanisms Driving Cardiovascular Disease in Hutchinson-Gilford Progeria Syndrome: Lessons Learned from Animal Models.
    Benedicto I; Dorado B; Andrés V
    Cells; 2021 May; 10(5):. PubMed ID: 34064612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies.
    Suzuki M; Jeng LJB; Chefo S; Wang Y; Price D; Li X; Wang J; Li RJ; Ma L; Yang Y; Zhang X; Zheng N; Zhang K; Joseph DB; Shroff H; Doan J; Pacanowski M; Smpokou P; Donohue K; Joffe HV
    Genet Med; 2023 Feb; 25(2):100335. PubMed ID: 36507973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular Smooth Muscle-Specific Progerin Expression Accelerates Atherosclerosis and Death in a Mouse Model of Hutchinson-Gilford Progeria Syndrome.
    Hamczyk MR; Villa-Bellosta R; Gonzalo P; Andrés-Manzano MJ; Nogales P; Bentzon JF; López-Otín C; Andrés V
    Circulation; 2018 Jul; 138(3):266-282. PubMed ID: 29490993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular smooth muscle cell loss underpins the accelerated atherosclerosis in Hutchinson-Gilford progeria syndrome.
    Hamczyk MR; Andrés V
    Nucleus; 2019 Dec; 10(1):28-34. PubMed ID: 30900948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired LEF1 Activation Accelerates iPSC-Derived Keratinocytes Differentiation in Hutchinson-Gilford Progeria Syndrome.
    Mao X; Xiong ZM; Xue H; Brown MA; Gete YG; Yu R; Sun L; Cao K
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Progerin Suppression and Lamin A Restoration Rescue Hutchinson-Gilford Progeria Syndrome.
    Sánchez-López A; Espinós-Estévez C; González-Gómez C; Gonzalo P; Andrés-Manzano MJ; Fanjul V; Riquelme-Borja R; Hamczyk MR; Macías Á; Del Campo L; Camafeita E; Vázquez J; Barkaway A; Rolas L; Nourshargh S; Dorado B; Benedicto I; Andrés V
    Circulation; 2021 Nov; 144(22):1777-1794. PubMed ID: 34694158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects.
    Zhang J; Lian Q; Zhu G; Zhou F; Sui L; Tan C; Mutalif RA; Navasankari R; Zhang Y; Tse HF; Stewart CL; Colman A
    Cell Stem Cell; 2011 Jan; 8(1):31-45. PubMed ID: 21185252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progerin-expressing endothelial cells are unable to adapt to shear stress.
    Danielsson BE; Peters HC; Bathula K; Spear LM; Noll NA; Dahl KN; Conway DE
    Biophys J; 2022 Feb; 121(4):620-628. PubMed ID: 34999130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome.
    Gordon CM; Cleveland RH; Baltrusaitis K; Massaro J; D'Agostino RB; Liang MG; Snyder B; Walters M; Li X; Braddock DT; Kleinman ME; Kieran MW; Gordon LB
    Bone; 2019 Aug; 125():103-111. PubMed ID: 31077852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
    Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
    J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation.
    Gordon LB; Norris W; Hamren S; Goodson R; LeClair J; Massaro J; Lyass A; D'Agostino RB; Tuminelli K; Kieran MW; Kleinman ME
    Circulation; 2023 Jun; 147(23):1734-1744. PubMed ID: 36919608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reprogramming progeria fibroblasts re-establishes a normal epigenetic landscape.
    Chen Z; Chang WY; Etheridge A; Strickfaden H; Jin Z; Palidwor G; Cho JH; Wang K; Kwon SY; Doré C; Raymond A; Hotta A; Ellis J; Kandel RA; Dilworth FJ; Perkins TJ; Hendzel MJ; Galas DJ; Stanford WL
    Aging Cell; 2017 Aug; 16(4):870-887. PubMed ID: 28597562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.
    Gordon LB; Shappell H; Massaro J; D'Agostino RB; Brazier J; Campbell SE; Kleinman ME; Kieran MW
    JAMA; 2018 Apr; 319(16):1687-1695. PubMed ID: 29710166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Premature Vascular Aging with Features of Plaque Vulnerability in an Atheroprone Mouse Model of Hutchinson-Gilford Progeria Syndrome with
    Nevado RM; Hamczyk MR; Gonzalo P; Andrés-Manzano MJ; Andrés V
    Cells; 2020 Oct; 9(10):. PubMed ID: 33049978
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.